The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Real-world efficacy and safety of selinexor in R/R multiple myeloma
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses findings from a study which analyzed real-world data (RWD) on the efficacy and safety of selinexor combinations in patients with relapsed/refractory (R/R) multiple myeloma. Overall, results were similar to prior clinical trial data, and Prof. Kastritis outlines two interesting findings from the analysis on dosing and the prognostic impact of low serum albumin. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
